Retinoids, Interferon α, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RARα mediates the antiangiogenic effect of retinoids

Majewski, S.; Marczak, Maria; Szmurło, A.; Jabłońska, Stefania; Bollag, W.

doi:10.1016/0304-3835(95)90166-3

Cited by 44 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, RA caused endothelial cells to become refractory to stimulation by either tumor-conditioned media or various angiogenic factors without interfering with cell proliferation [64]. In addition, there is evidence that the antitumor activity of retinoids involves inhibition of tumor-induced angiogenesis [64,65,66]. …”

Section: Discussionmentioning

confidence: 99%

A Role for All-Trans-Retinoic Acid in the Early Steps of Lymphatic Vasculature Development

et al. 2010

View full text Add to dashboard Cite

The molecular mechanisms that regulate the earliest steps of lymphatic vascular system development are unknown. To identify regulators of lymphatic competence and commitment, we used an in vitro vascular assay with mouse embryonic stem cell-derived embryoid bodies (EBs). We found that incubation with retinoic acid (RA) and, more potently, with RA in combination with cAMP, induced the expression of the lymphatic competence marker LYVE-1 in the vascular structures of the EBs. This effect was dependent on RA receptor (RAR)-α and protein kinase A signaling. RA-cAMP incubation also promoted the development of CD31+/LYVE-1+/Prox1+ cell clusters. In situ studies revealed that RAR-α is expressed by endothelial cells of the cardinal vein in ED 9.5–11.5 mouse embryos. Timed exposure of mouse and Xenopus embryos to excess of RA upregulated LYVE-1 and VEGFR-3 on embryonic veins and increased formation of Prox1-positive lymphatic progenitors. These findings indicate that RA signaling mediates the earliest steps of lymphatic vasculature development.

show abstract

Section: Discussionmentioning

confidence: 99%

A Role for All-Trans-Retinoic Acid in the Early Steps of Lymphatic Vasculature Development

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In our studies, using Skv keratinocyte line bearing human papillomavirus type 16 (HPV16) and tumor-cell induced angiogenesis assay (for technical details see [68,69] we found that tumorigenic Skv cell line, when injected intradermally into X-ray-immunosuppressed Balb/c mice, induced a strong angiogenic reaction, as compared to that of non-tumorigenic variant of cancer Skv cells (Fig. 1).…”

Section: Immunosuppressive Potential Of Vitamin D Analogsmentioning

confidence: 87%

“…However vitamin D derivatives with relatively low toxicity were found to exert strong antiangiogenic effects in various experimental models [67][68][69][70].…”

Section: Immunosuppressive Potential Of Vitamin D Analogsmentioning

confidence: 99%

Vitamin D Analogs in Cutaneous Malignancies

Majewski¹,

Kutner²,

Jabłońska³

2000

CPD

View full text Add to dashboard Cite

In this article are reviewed available experimental and clinical studies and vitamin D analogs, and molecular and cellular mechanisms of their antineoplastic activity. In more detail are discussed the antiproliferative and pro-differentiative effects, inhibition of tumor-induced angiogenesis and induction of apoptosis. The use of vitamin D analogs is however hampered by their toxicity. In various experimental systems it was shown that the activities of vitamin D analogs can be enhanced by combined application with retinoids or other biological active compounds such as cytokines and growth factors. Retinoids and vitamin D analogs were found to have synergistic inhibitory effects on tumor cell proliferation and angiogenic capability, and both agents applied simultaneously are efficacious in small doses. Thus combined therapy could find application in clinical practice. There are up to now only very limited data on the treatment of cutaneous malignancies with vitamin D analogs and it appears that a combined therapy, preferably with retinoids, could be more beneficial. The new synthetic, more potent and less calcemic analogs might find wide application in chemotherapy of premalignant and early malignant cutaneous tumors and could be especially useful for chemoprevention in the high-risk groups, e.g., xeroderma pigmentosum, organ transplant recipients, arsenical keratoses and others.

show abstract

“…9-Cis-retinoic acid also augmented 1,25-(OH) 2 D 3 -, and vitamin D analog-induced growth inhibition of HL-60 cells and LNCaP prostate carcinoma cells [42,50,155]. Besides growth and differentiation effects, the combination of 1,25-(OH) 2 D 3 and various isomers of retinoic acid were more potent in reducing angiogenesis than each compound alone [117,118,156]. The background of the interaction between retinoids and 1,25-(OH) 2 D 3 may be attributed to heterodimer formation of their respective receptors [157].…”

Section: 25-(oh) 2 D 3 and Vitamin D Analogs In Cancer Patientsmentioning

confidence: 96%

“…It was shown that intraperitoneal injection of 1,25-(OH) 2 D 3 inhibited blood vessel formation in retinoblastomas in mice [116]. 1,25-(OH) 2 D 3 and vitamin D analog treatment of immunosuppressed mice injected with human transformed keratinocyte, breast carcinoma, and vulval carcinoma cell lines resulted in significantly decreased tumor-induced angiogenesis [117][118][119]. The way in which 1,25-(OH) 2 D 3 inhibits angiogenesis is not clear, but may be via inhibition of growth factors or via specific oncogenes or tumor suppressor genes [119][120][121][122][123].…”

Section: Differentiationmentioning

confidence: 99%

Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs

Bemd

Pols²,

Leeuwen³

2000

CPD

View full text Add to dashboard Cite

The role of 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) as a regulator of cell growth and differentiation is well recognized. Currently, 1, 25-(OH)2D3 and vitamin D analogs are being evaluated for their therapeutic potential in the treatment of hyperproliferative disorders like cancer. In the present review, we will discuss several processes that might be involved in 1,25-(OH)2D3- and vitamin D analog-mediated suppression of cancer cell growth. The effects on tumor cell proliferation, differentiation, apoptosis, angiogenesis, metastases, and parathyroid hormone-related peptide secretion will be highlighted. In addition, combination therapy with other tumor effec tive drugs will be addressed. Furtermore, we will focus on the potential drawbacks and the possible side effects of vitamin D compounds in the treatment of cancer.

show abstract

Retinoids, Interferon α, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RARα mediates the antiangiogenic effect of retinoids

Cited by 44 publications

References 22 publications

A Role for All-Trans-Retinoic Acid in the Early Steps of Lymphatic Vasculature Development

A Role for All-Trans-Retinoic Acid in the Early Steps of Lymphatic Vasculature Development

Vitamin D Analogs in Cutaneous Malignancies

Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs

Contact Info

Product

Resources

About